Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Immunotherapy

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Early 2026 momentum reflects surging Anktiva revenue alongside Saudi clearance opening a new market.

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC